Stock 6535 LUMOSA THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange
Other stock markets
 18:00:00 2024-06-04 EDT 		5-day change 1st Jan Change
189.5 TWD +4.70% Intraday chart for Lumosa Therapeutics Co., Ltd. -2.32% +177.45%
05-14 Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-14 Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson
CI
Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative
CI
Lumosa Therapeutics Co., Ltd. announced that it expects to receive TWD 50 million in funding
CI
Lumosa Therapeutics Co., Ltd. cancelled the transaction announced on May 31, 2023
CI
GenEditBio Limited announced that it has received funding from Lumosa Therapeutics Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited, Innovation & Technology Fund Company, Hong Kong Science and Technology Parks, Investment Arm
CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke
CI
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001
CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection
CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke
CI
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee
CI
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director
CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction
CI
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer
CI
Lumosa Therapeutics Co., Ltd. announced a financing transaction
CI
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6535 Stock
  4. News Lumosa Therapeutics Co., Ltd.